Negative regulation of ceramide biosynthetic process

Across TCGA pan-cancer cohorts, RNA activity of the Negative regulation of ceramide biosynthetic process pathway differs between tumor and matched normal tissue in 11 of the 18 cancer types tested.

The strongest signal is observed in thyroid carcinoma (THCA), where pathway activity is higher in tumor tissue than in matched normal tissue. In most cancer types, this pathway shows higher activity in tumors, although a few cancer types, such as KIRC and KICH, show the opposite pattern, with lower activity in tumor tissue.

THCA, HNSC, and BLCA show the most reproducible tumor–normal differences in pathway activity.

Tumor vs normal pathway activity by lineage

Ranked by sampling consensus. Activity change represents the tumor-versus-normal difference in pathway activity on a log₂ scale. Positive values indicate higher pathway activity in tumor tissue. The reported p-values are derived from the corresponding differential activity tests.

Lineage	Gender	Stage	Activity change	p	Sampling consensus
THCA	Male	III,IV	+0.115	<.001	10	view →
HNSC	Male	IV	+0.077	.001	8	view →
BLCA	Male	All	+0.078	.001	7	view →
COAD	All	II,III,IV	+0.042	<.001	7	view →
LUAD	All	II,III,IV	+0.048	.001	6	view →
KIRC	Male	All	−0.037	<.001	6	view →
LUSC	Male	All	+0.069	<.001	4	view →
KICH	All	All	−0.057	<.001	4	view →
LIHC	All	All	+0.030	<.001	4	view →
STAD	All	II,III,IV	+0.049	.025	2	view →
CHOL	Female	All	+0.139	.008	1	view →

Pink = more active in tumor, green = less active in tumor. Showing the 11 strongest of 11 lineages.

GO:1900060–THCA

Open the THCA breakdown →